scholarly journals Whole-Grain Processing and Glycemic Control in Type 2 Diabetes: A Randomized Crossover Trial

Diabetes Care ◽  
2020 ◽  
Vol 43 (8) ◽  
pp. 1717-1723 ◽  
Author(s):  
Sebastian Åberg ◽  
Jim Mann ◽  
Silke Neumann ◽  
Alastair B. Ross ◽  
Andrew N. Reynolds
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Crossover Trial ◽  
Whole Grain ◽  
Grain Processing ◽  
Randomized Crossover Trial

Time‐Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial

Obesity ◽  
2019 ◽  
Author(s):  
Amy T. Hutchison ◽  
Prashant Regmi ◽  
Emily N.C. Manoogian ◽  
Jason G. Fleischer ◽  
Gary A. Wittert ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Glucose Tolerance ◽  
Crossover Trial ◽  
Restricted Feeding ◽  
Randomized Crossover Trial

Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial

2021 ◽  
Author(s):  
Ellen Boswijk ◽  
Marlies de Ligt ◽  
Marie-Fleur J Habets ◽  
Alma M.A. Mingels ◽  
Wouter D. van Marken Lichtenbelt ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Crossover Trial ◽  
Placebo Treatment ◽  
Fdg Uptake ◽  
Resveratrol Treatment ◽  
Randomized Crossover Trial ◽  
Arterial Inflammation ◽  
18F Fdg

Abstract Purpose Resveratrol has shown promising anti-inflammatory effects in in vitro and animal studies. We aimed to investigate this effect on arterial inflammation in vivo. Methods This was an additional analysis of a double-blind randomized crossover trial which included eight male subjects with decreased insulin sensitivity who underwent an 18F-fluoroxyglucose (18F-FDG) PET/CT after 34 days of placebo and resveratrol treatment (150 mg/day). 18F-FDG uptake was analyzed in the carotid arteries and the aorta, adipose tissue regions, spleen, and bone marrow as measures for arterial and systemic inflammation. Maximum target-to-background ratios (TBRmax) were compared between resveratrol and placebo treatment with the non-parametric Wilcoxon signed-rank test. Median values are shown with their interquartile range. Results Arterial 18F-FDG uptake was non-significantly higher after resveratrol treatment (TBRmax all vessels 1.7 (1.6–1.7)) in comparison to placebo treatment (1.5 (1.4–1.6); p=0.050). Only in visceral adipose tissue, the increase in 18F-FDG uptake after resveratrol reached statistical significance (p=0.024). Furthermore, CRP-levels were not significantly affected by resveratrol treatment (p=0.091). Conclusions Resveratrol failed to attenuate arterial or systemic inflammation as measured with 18F-FDG PET in subjects at risk of developing type 2 diabetes. However, validation of these findings in larger human studies is needed.

Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial

2007 ◽  
Vol 9 (3) ◽  
pp. 394-407 ◽  
Author(s):  
S. S. Lund ◽  
L. Tarnow ◽  
C. D. A. Stehouwer ◽  
C. G. Schalkwijk ◽  
M. Frandsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Crossover Trial ◽  
Obese Patients ◽  
Randomized Crossover Trial

Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial

2007 ◽  
Vol 154 (1) ◽  
pp. 78.e1-78.e7 ◽  
Author(s):  
Letícia Weiss Ribeiro ◽  
Jorge P. Ribeiro ◽  
Ricardo Stein ◽  
Cristiane Leitão ◽  
Carísi Anne Polanczyk
Keyword(s):  
Type 2 Diabetes ◽  
Crossover Trial ◽  
Randomized Crossover Trial

scholarly journals Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial

2021 ◽  
Author(s):  
Charlotte K. Boughton ◽  
Afroditi Tripyla ◽  
Sara Hartnell ◽  
Aideen Daly ◽  
David Herzig ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Primary Endpoint ◽  
Glucose Control ◽  
Closed Loop ◽  
Crossover Trial ◽  
Open Label ◽  
Randomized Crossover Trial ◽  
Target Glucose

AbstractWe evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 ± 11 years (mean ± s.d.), diabetes duration of 20 ± 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart (‘closed-loop’) with standard insulin therapy and a masked continuous glucose monitor (‘control’) in random order. The primary endpoint was time in target glucose range (5.6–10.0 mmol l−1). Thirteen participants received closed-loop first and thirteen received control therapy first. The proportion of time in target glucose range (5.6–10.0 mmol l−1; primary endpoint) was 52.8 ± 12.5% with closed-loop versus 37.7 ± 20.5% with control; mean difference, 15.1 percentage points (95% CI 8.0–22.2; P < 0.001). Mean glucose was lower with closed-loop than control (10.1 ± 1.3 versus 11.6 ± 2.8 mmol l−1; P = 0.003). Time in hypoglycemia (<3.9 mmol l−1) was reduced with closed-loop versus control (median (IQR) 0.1 (0.0–0.4%) versus 0.2 (0.0–0.9%); P = 0.040). No severe hypoglycemia events occurred during the control period, whereas one severe hypoglycemic event occurred during the closed-loop period, but not during closed-loop operation. Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. The trial registration number is NCT04025775.

Sign in / Sign up

Export Citation Format

Share Document